Charlotte Fribert
Chief Executive Officer Bonsai Biotherapeutics
Charlotte Fribert, PhD, is CEO of Bonsai Biotherapeutics, a biopharmaceutical company developing antigen-specific immune tolerance therapies for autoimmune diseases. She has extensive experience spanning immunology, biotechnology, drug development, and biotech company leadership. Prior to Bonsai, she served as CEO of Toleranzia and previously worked as Project Director in pharmaceutical development at AstraZeneca. Earlier in her career, she founded and led the Paris-based vaccine company Epixis SA, which was subsequently acquired by VBI Vaccines. Charlotte studied medicine at Karolinska Institutet and Université Pierre et Marie Curie in Paris and holds a PhD in immunology and biotechnology. Her work has focused on translating innovative immunological concepts into clinically relevant therapeutic programs.
Seminars
Review current levels of pharma and investor engagement with antigen-specific approaches to identify what would strengthen confidence in the space and positioning the field to attract deeper investment going forward.
- Understand what Big Pharma considers a commercially attractive indication and how they come to this decision to inform biotechs of what steps can support successful commercialization
- Discussing the type of data and evidence pharma and investors have indicated they want to see to clarify the gap between what is currently available and what may be expected, and explore how early-stage programs can prepare for this
- Considering how indication choice and commercial viability factor into investment decisions, to weigh biological rationale against practical, market-driven considerations, and inform how programs might frame their own value proposition
- Evaluating the novel mechanistic insights from this year’s program
- Assessing the preclinical data shared and looking to the next year’s clinical therapeutic landscape
- Supercharging antigen-specific immune tolerance therapies to the clinic – what can the field do together to make the promise of the technology a reality?
